Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MBOAT4 | Q96T53 | 3/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.40 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.40 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.37 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9318312 | 0.77 | MBOAT4 (0.50) | MBOAT4CDK5CDK5R1NR1I3CYP19A1 | |
| SCHEMBL7802581 | 0.72 | SRD5A1 (0.58) | — | |
| SCHEMBL7527164 | 0.72 | SRD5A1 (0.58) | — | |
| SCHEMBL7050061 | 0.71 | AR (0.36) | MBOAT4CDK5CDK5R1NR1I3CYP19A1 | |
| SCHEMBL10701146 | 0.71 | NR1I3 (0.39) | MBOAT4NR1I3CYP19A1GRIN1GRIN2B | |
| SCHEMBL14300609 | 0.70 | AR (0.64) | — | |
| SCHEMBL9113552 | 0.70 | AR (0.64) | — | |
| SCHEMBL9221841 | 0.70 | AR (0.64) | — | |
| SCHEMBL8076029 | 0.69 | NR1I3 (0.47) | CDK5CDK5R1NR1I3CYP19A1GRIN1 | |
| SCHEMBL8604667 | 0.69 | MBOAT4 (0.42) | MBOAT4CDK5CDK5R1NR1I3CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1467739-A4 | 17-HYDROXY-4-AZA-ANDROSTAN-3-ONES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO INC (US) | 2008-01-09 | — | — | EP | claimed |
| US-20050107416-A1 | 17-hydroxy 4-aza androstan -3-ones as androgen receptor modulators | MERCK SHARP & DOHME CORP. | 2005-05-19 | — | — | US | claimed |
| EP-1467739-A2 | 17-HYDROXY-4-AZA-ANDROSTAN-3-ONES AS ANDROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2004-10-20 | — | — | EP | claimed |
| WO-2003059293-A2 | 17-HYDROXY-4-AZA-ANDROSTAN-3-ONES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2003-07-24 | — | — | WO | claimed |
| US-7605152-B2 | 17-hydroxy-4-aza-androstan-3-ones as androgen receptor modulators | MERCK & CO., INC. (US) | 2009-10-20 | — | — | US | disclosed |
| EP-1467739-A4 | 17-HYDROXY-4-AZA-ANDROSTAN-3-ONES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO INC (US) | 2008-01-09 | — | — | EP | disclosed |
| US-20050107416-A1 | 17-hydroxy 4-aza androstan -3-ones as androgen receptor modulators | MERCK SHARP & DOHME CORP. | 2005-05-19 | — | — | US | disclosed |
| EP-1467739-A2 | 17-HYDROXY-4-AZA-ANDROSTAN-3-ONES AS ANDROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2004-10-20 | — | — | EP | disclosed |
| WO-2003059293-A2 | 17-HYDROXY-4-AZA-ANDROSTAN-3-ONES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107416-A1 | 17-hydroxy 4-aza androstan -3-ones as androgen receptor modulators | SHBG, CYP19A1, NR5A1 | MBOAT4 787/4885CDK5 2174/4885CDK5R1 569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.